GlassScriptPhysician profile
Monica Salgueiro
NPI 1962670968
$12,059.00
in general payments reported to CMS, 2019-2025
25 companies · $4,956 in 2025
The $4,956 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $79.69 · 2021: $345 · 2022: $2,001 · 2023: $1,995 · 2024: $2,415 · 2025: $4,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,181 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,180.60 |
| Education | $185.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,722.56 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,469.72 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $1,397.80 | 2021-2025 | Azstarys, Azstarys |
| Otsuka America Pharmaceutical, INC. | $925.60 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $774.77 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $767.41 | 2022-2025 | Vraylar |
| Bausch Health US, LLC | $669.35 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $643.82 | 2021-2025 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $613.88 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $604.63 | 2020-2025 | Dyanavel Xr |
| Lundbeck LLC | $533.45 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $317.04 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $295.46 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $284.05 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $228.47 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $189.55 | 2025 | |
| Sunovion Pharmaceuticals INC. | $134.82 | 2019-2022 | |
| Almatica Pharma LLC | $124.84 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Vanda Pharmaceuticals INC. | $120.76 | 2022-2025 | Fanapt, Hetlioz |
| Adlon Therapeutics L.P. | $71.66 | 2021 | |
| Collegium Pharmaceutical, INC. | $65.50 | 2025 | Jornay Pm |
| Indivior INC. | $42.67 | 2024 | Perseris |
| Luye Pharma (USA) LTD. | $25.06 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $19.94 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $16.19 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Salgueiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.